GSK3B and Alzheimer disease: GSK3β dysregulation, an increased and sustained activation of this signalling pathway, initiates and promotes chronic neuroinflammation and contributes to development of AD brain pathology (excessive tau phosphorylation and formation of NFT, excessive amyloid-β production and production of toxic monomers and oligomers) and accelerated cognitive decline by inhibiting neurogenesis, synaptic function and memory formation [115].